Navigation Links
MIT Receives First ARRONAX Shipment, Launching Strontium-82 Validation Project
Date:2/21/2012

LUBBOCK, Texas, Feb. 21, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 16, 2012, MIT, received its first shipment of strontium-82(Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France. 

This historic event marks the first shipment of Sr-82 to be received by a private, non-government, entity in the U.S. in support of Sr-82 production. The receipt of this material also marks the beginning of MIT's validation efforts in order to qualify Sr-82 product material as Active Pharmaceutical Ingredient (API).

Over the next six months MIT will continue to obtain Sr-82 target solutions, from foreign irradiators at the facility in Lubbock, Texas.  MIT will conduct the critical processing procedures for final purification into API grade Sr-82.  Validation of the API grade Sr-82 product material is key to the Positron/MIT 2012 Drug Master File submission to the U.S. FDA.

"With the receipt of Sr-82 from ARRONAX, Positron and MIT have achieved an incredible milestone," states MIT President and Positron Pharmaceutical, Chief Technical Officer, Jason Kitten. "Up until this point in time, the Department of Energy was the only organization in the United States capable of processing Sr-82 material. By executing our plans, MIT is well positioned to meet the Drug Master File qualifications, which will further advance and accelerate Positron's Sr-82 mission. Positron continues its progress and is on schedule to meet 2012 Sr-82 supply objectives. Positron's goal of solidifying and advancing cardiac PET's progression in the U.S. is well underway."

About Positron:

Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services
'/>"/>

SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
2. The Apothecary Shops Receives Exclusive Distribution Rights for Mitosol®
3. Waltonen Engineering, Inc., Receives GSA Schedule
4. Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed
5. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
6. Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wifes Organs
7. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
8. Large Orthopedic Practice Receives Vizteks Complete Orthopedic DR+PACS Bundle
9. Ocular Therapeutix, Inc. Receives IDE Approval to Conduct a Pivotal Clinical Trial for ReSure™ Sealant
10. United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
11. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Imprimis Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of proprietary compounded drug therapies, today ... financial results on Wednesday, May 13, 2015.  The company ... (1:30 p.m. PDT) on the same day to discuss ... The conference call and webcast will be open to ...
(Date:5/4/2015)... 4, 2015 EspeRare today announced ... Orphan Drug Designation (ODD) for rimeporide, its lead compound ... is a rare, life-threatening disease affecting boys early in ... is the most common and serious form of paediatric ... exchanger type-1 inhibitor, originally developed by Merck Serono in ...
(Date:5/1/2015)... CHAPEL HILL, N.C. , May 1, 2015 /PRNewswire/ ... from payers for its high price but manufacturer Gilead ... programs, strategic worldwide pricing, and effective public relations campaigns. ... and promise of less severe side effects propelled the ... quarter of 2014, the therapy,s first quarter on the ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 3EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2
... Inc. (Nasdaq: STXS ) announced today financial results ... line with the preliminary results reported on October 13, 2010. ... margins, and reductions in both operating loss and net loss. ... million, compared to $13.3 million in the third quarter 2009. ...
... 2010 Cambrex Corporation (NYSE: CBM ) ... released on Wednesday, November 3, 2010 after the market ... conference call to discuss the third quarter 2010 financial ... November 4, 2010 at 8:30 a.m. Eastern Time Dial-in: ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become parents, Astroglide ... TTC™ (Trying to Conceive) . Unlike traditional lubricants that ... TTC™ is specially formulated to provide a better environment ... Disease Control, an average of one in eight ... pregnancy, and over 7.4 million women have ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... 2015 “St. Louis has long represented ... the West,” so it is the perfect place for ... Dr. Ben Litalien, Chief Development Officer for Zerorez. ... and will provide veterans with a $10,000 discount on ... to have a number of Military Veterans in its ...
(Date:5/3/2015)... 03, 2015 AvePoint, ... platforms and devices, today announced it is a ... Professionals (IAPP) Asia Privacy Forum, taking place May ... the event, AvePoint will showcase its compliance, risk, ... platforms. , Visit AvePoint for New Solutions ...
Breaking Medicine News(10 mins):Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... hernias are one of the most common conditions treated ... annually. Although ventral hernia repair (VHR) is a common ... infection has been identified as a consistent risk factor ... which appears in the November issue of The ...
... such as Viagra use is linked to development of vision ... disorders have used Viagra medicines. It is found that it ... cause risk of blindness. Men most at risk for the ... heart disease, high blood pressure and high cholesterol, among other ...
... Findings presented at the American Society of Therapeutic Radiation ... antigen (PSA) // significantly reduces the mortality associated with ... most prevalent type of cancer found in men after ... in the male reproductive system, which produces some of ...
... is essential for the lipid and carbohydrate metabolism, and ... to insulin.// The use of glucose by the peripheral ... has potential impact on long-term complications. ,In ... and an association between the proper metabolic control and ...
... and colleagues have identified a candidate gene, Sipa1, ... in cancer. Cancer mortality is most often the ... studies from Kent Hunter’s group demonstrated that the ... efficiency. They expressed the polyoma middle-T transgene in ...
... in women after menopause has been found to enhance ... cholesterol (the “good” cholesterol) in women, according to a ... and is characterized by decreased levels of the female ... the vagina and uterus. In addition the hormone ...
Cached Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Impotence drug such as Viagra may cause Vision Loss 2Health News:Carnitine deficiency in children and adolescents with type 1 diabetes 2Health News:Researchers Identify Sipa 1 Gene, Responsible For Cancer Metastasis 2Health News:Testosterone Therapy can improve sexual function in postmenopausal women 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: